ELCC 2016 | Targeting PD-1 and PD-L1 for lung cancer therapy

Joseph Paul Eder

At the 6th European Lung Cancer Conference (ELCC), held in Geneva, Switzerland, from 13–16 April 2016, Joseph Paul Eder, MD, from Yale University Cancer Center, New Haven, CT, explains the development of antibodies targeting the programmed death ligand 1 (PD-L1) and its receptor, programmed death 1 (PD-1) for the treatment of patients with non-small cell lung cancer (NSCLC), including clinical trials evaluating the integration of PD-1/PD-L1–blocking antibodies with existing standard-of-care approaches.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter